Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci

Clinical Infectious Diseases

Volumn 35, Issue 10, 2002, Pages 1139-1146

  Zaas, Aimee K ^a,b   Song, Xiaoyan ^a   Tucker, Pamela ^a   Perl, Trish M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; IMIPENEM; OXACILLIN; PENICILLIN DERIVATIVE; RIFAMPICIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CANCER PATIENT; DIABETES MELLITUS; ENTEROCOCCUS; FEMALE; HOSPITAL INFECTION; HUMAN; IATROGENIC DISEASE; INFECTION RISK; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEPTICEMIA;

BACTEREMIA; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; VANCOMYCIN RESISTANCE;

EID: 0037111760     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342904     Document Type: Article

References (29)

1. Martone WJ. Spread of vancomycin-resistant enterococci: Why did it happen in the United States? Infect Control Hosp Epidemiol 1998; 19: 539-45.
2. Huycke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future. Emerg Infect Dis 1998; 4:239-49.
3. Bhorade SM, Christenson J, Pohlman AS, Arnow PM, Hall JB. The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients. Chest 1999; 115:1085-91.
4. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: Risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20:318-23.
5. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172:993-1000.
6. Bonten MJ, Slaughter S, Ambergen AW, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: An important infection-control variable. Arch Intern Med 1998; 158:1127-32.
7. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality. Clin Infect Dis 1996; 23:1234-9.
8. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: Comparison of clinical features and outcomes. Clin Infect Dis 1998; 26:1127-33.
9. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection. Clin Infect Dis 1995; 20:1126-33.
10. Montecalvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994; 38:1363-7.
11. Roghmann MC, McCarter RJ, Brewrink J, Cross AS, Morris JG. Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin Infect Dis 1997; 25:1056-9.
12. Garner JS. Guidelines for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996; 17:53-80.
13. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40.
14. Kuehnert MJ, Jernigan JA, Pullen AL, Rimland D, Jarvis WR. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 1999; 20:660-3.
15. Mainous MR, Lipsett PA, O'Brien M. Enterococcal bacteremia in the surgical intensive care unit: does vancomycin resistance affect mortality? Johns Hopkins SICU Study Group. Arch Surg 1997; 132:76-81.
16. Dever LL, Handwerger S. Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice. Microb Drug Resist 1996; 2:415-21.
17. Whitman MS, Pitsakis PG, DeJesus E, Osborne AJ, Levison ME, Johnson CC. Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model. Antimicrob Agents Chemother 1996; 40:1526-30.
18. Greene JN, Linch DC, Miller CB. Current treatments for infection in neutropenic patients with hematologic malignancy. Oncology 2000; 14(Suppl 6):31-4.
19. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343:1925-32.
20. Bonten MJ, Hayden MK, Nathan C, et al. Epidemiology of patients and environments with vancomycin-resistant enterococci. Lancet 1996; 348:1615-9.
21. Yu VL. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med 1981; 94:784-5.
22. Pallares R, Pujol M, Pena C, Ariza J, Martin R, Gudiol F. Cephalosporins as risk factor for nosocomial Enterococcus faecalis bacteremia: A matched case-control study. Arch Intern Med 1993; 153:1581-6.
23. Kirkpatrick BD, Harrington SM, Smith D, et al. An outbreak of van-comycin-dependent enterococci in a bone marrow transplant unit. Clin Infect Dis 1999; 29:1268-73.
24. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 1999; 180:384-90.
25. Nord CE, Brismar B, Kasholm-Tengve B, Tunevall G. Effect of piper-acillin/tazobactam therapy on intestinal microflora. Scand J Infect Dis 1992; 24:209-13.
26. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996; 23:767-72.
27. Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000; 30:466-72.
28. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: A systematic review. Clin Infect Dis 2001; 32:1055-61.
29. Kapur D, Dorsky D, Feingold JM, et al. Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 25:147-52.